25 (美东时间)

2003 FDA批准的在美国市场化销售的28种药物

药品名	商标名	制药厂	药物分类	给药途径	FDA 分类^a
Humira	Adalimumab^b	Abbott	抗关节炎	皮下注射	S^c
Fabrazyme	Agalsidase beta	Genzyme	抗纤维化疾病	静脉注射	P, H, V^c
Amevive	Alefacept	Biogen	抗牛皮癣	肌肉	S^b
Uroxatral	Alfuzosin hydrochloride	Sanofi-Synthélabo	抗良性前聂腺增生	口服	1-S
Emend	Aprepitant	默克	抗呕吐	口服	1-P
Reyataz	Atazanavir sulfate	Bristol-Myers Squibb	抗病毒	口服	1-P
Strattera	Atomoxetine hydrochloride^b	Lilly	治疗多动症和注意力不集中	口服	1-S
Velcade	Bortezomib	Millennium	抗癌症	静脉注射	1-P, H
Cubicin	Daptomycin	Cubist	抗菌素	静脉注射	1-P
Raptiva	Efalizumab	Genentech; Xoma	治疗牛皮癣	Subcutaneous	S^c
Relpax	Eletriptan hydrobromide^b	辉瑞	抗偏头痛	口服	1-S
Emtriva	Emtricitabine	Gilead Sciences	抗病毒	口服	1-S
Fuzeon	Enfuvirtide	Roche; Trimeris	抗病毒	Subcutaneous	1-P, H
Inspra	Eplerenone^c	辉瑞	治疗充血性心脏病和高血压	口服	1-S
Iressa	Gefitinib	AstraZeneca	抗癌	口服	1-P, H
Extraneal	Icodextrin^b	Baxter	腹部透晰	Peritoneal	1-S
Aldurazyme	Laronidase	Genzyme	粘多糖病	静脉注射	P, V^c
Namenda	Memantine hydrochloride	Forest	老年痴呆	口服	1-S, V
Solagé	Mequinol/tretinoin^b	Galderma	皮肤漂白	表皮	1, 4-S
Zavesca	Miglustat	Actelion	Gaucher病(一种失算,震颤,失言等症状的神经性疾病)	口服	1-S, V
Alinia	Nitazoxanide^b	Romark	抗寄生虫	口服	1-P, V
Xolair	Omalizumab	Genentech; Novartis	抗哮喘	Subcutaneous	S^c
Aloxi	Palonosetron hydrochloride	MGI Pharma	抗呕吐剂	静脉注射	1-S
Somavert	Pegvisomant	辉瑞	肢端肥大症治疗	Subcutaneous	1-P, V
Crestor	Rosuvastatin calcium	AstraZeneca	抗高脂血症	口服	1-S
Cialis	Tadalafil	Lilly; ICOS	勃起功能障碍	口服	1-S
Bexxar	Tositumomab and iodine I-131 tositumomab	Corixa; GlaxoSmithKline	抗高脂血症	静脉注射	P^c
Levitra	Vardenafil hydrochloride	Bayer; GlaxoSmithKline	勃起功能障碍	口服	1-S

a	FDA classification of new drugs: 1 = new molecular entity; 4 = combination product; P = priority review; S = standard review; H = accelerated approval; V = designated orphan drug.
b	Approved by FDA before 2003 but not marketed until 2003.
c	A biological approved through an FDA procedure that does not assign a numerical classification.

[ Back ] [ Home ] [ Up ] [ Next ]